|
|
|
201-500 employees
View all
|
|
Pharmaceuticals
|
|
15 Crosby Drive, Bedford, MA 01730, US
|
|
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our robust product pipeline positions Ocular Therapeutix to become a leader in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current standard of care by developing sustained release alternatives. With a focus on advancing our products through to Phase 3 clinical trials, our intention is to develop a commercially viable portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing for better patient outcomes.
|
Ocular Therapeutix, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
100%
|
The widely used Ocular Therapeutix, Inc. email format is {f}{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Ocular Therapeutix, Inc. customer service number in your country click here to find.
Antony Mattessich is the CEO of Ocular Therapeutix, Inc.. To contact Antony Mattessich email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.